Amifampridine

Amifampridine (3,4-Diaminopyridine) is an orally active, potent and cell permeable voltage-gated potassium (Kv) channel blocker (PCB) . Amifampridine is efficacy in the reversal of BoNT/A (HY-P79153) intoxication. Amifampridine increases transmitter release from neuromuscular junctions (NMJs) . Amifampridine can be used for Lambert-Eaton myasthenic syndrome (LEMS) research[1][2][3].

Product Specifications

CAS Number

[54-96-6]

Product Name Alternative

3,4-Diaminopyridine

UNSPSC

12352005

Hazard Statement

H300+H330, H311, H319

Target

Potassium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Amifampridine.html

Purity

99.99

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

NC1=C(N)C=CN=C1

Molecular Formula

C5H7N3

Molecular Weight

109.13

Precautions

H300+H330, H311, H319

References & Citations

[1]Maarten J Titulaer, et al. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011 Dec;10 (12) :1098-107.|[2]T L Harris, et al. Lycopodium clavatum exine microcapsules enable safe oral delivery of 3,4-diaminopyridine for treatment of botulinum neurotoxin A intoxication. Chem Commun (Camb) . 2016 Mar 18;52 (22) :4187-90.|[3]Ojala KS, et al. A high-affinity, partial antagonist effect of 3,4-diaminopyridine mediates action potential broadening and enhancement of transmitter release at NMJs. J Biol Chem. 2021 Jan-Jun;296:100302.